Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement

Phase 4

Completed

Conditions: Musculoskeletal Pain
Hip Injuries

Interventions: Other: Physiological Saline
Drug: Bupivacaine hydrochloride

First Posted Date: 2015-12-15

Last Posted Date: 2016-10-12

Lead Sponsor: Parc de Salut Mar

Target Recruit Count: 100

Registration Number: NCT02630160

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain

Effect of Anesthesia in Fracture Healing

Phase 4

Completed

Conditions: Closed Fracture of Hip

Interventions: Drug: Bupivacaine
Drug: Sevoflurane

First Posted Date: 2015-12-03

Last Posted Date: 2017-11-21

Lead Sponsor: Cukurova University

Target Recruit Count: 30

Registration Number: NCT02621255

Locations: 🇹🇷
Ebru Biricik, Adana, Sarıçam, Turkey

Effect of Caudal Nalbuphine on Postoperative Analgesia in Children

Not Applicable

Completed

Conditions: Postoperative Pain

Interventions: Drug: Nalbuphine plus Bupivacaine
Drug: Bupivacaine

First Posted Date: 2015-12-02

Last Posted Date: 2020-04-07

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT02618876

Locations: 🇪🇬
Assiut University Hospital, Assiut, Egypt

Comparing Exparel & Ropivacaine for Pain Relief in Total Knee Arthroplasty

Not Applicable

Conditions: Knee Osteoarthritis

Interventions: Drug: Ropivacaine
Drug: Exparel

First Posted Date: 2015-11-18

Last Posted Date: 2017-04-27

Lead Sponsor: Monmouth Medical Center

Target Recruit Count: 200

Registration Number: NCT02607579

Locations: 🇺🇸
Monmouth Medical Center, Long Branch, New Jersey, United States

Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty

Phase 4

Withdrawn

Conditions: Acute Pain
Regional Anesthesia Morbidity

Interventions: Drug: bupivacaine
Drug: ropivacaine
Device: Adductor Canal Catheter
Device: Sham Adductor Canal Catheter

First Posted Date: 2015-11-13

Last Posted Date: 2021-12-15

Lead Sponsor: Thomas Jefferson University

Registration Number: NCT02603900

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Foot and Ankle Clinic Application for Liposomal Related Anesthetic

Phase 4

Completed

Conditions: Hindfoot Arthrodesis
Tibitalocalceal Arthrodesis
Ankle Arthrodesis

Interventions: Drug: Exparel

First Posted Date: 2015-10-26

Last Posted Date: 2020-10-29

Lead Sponsor: OrthoCarolina Research Institute, Inc.

Target Recruit Count: 36

Registration Number: NCT02586077

Locations: 🇺🇸
OrthoCarolina, PA, Charlotte, North Carolina, United States

Effect of Intrathecal vs Intraarticular Dexmedetomidine on Postoperative Pain Following Arthroscopy

Not Applicable

Completed

Conditions: Postoperative Pain

Interventions: Drug: Intrathecal Dexmedetomidine
Drug: Intraarticular Dexmedetomidine
Drug: Bupivacaine

First Posted Date: 2015-10-21

Last Posted Date: 2019-03-13

Lead Sponsor: Assiut University

Target Recruit Count: 90

Registration Number: NCT02581566

Locations: 🇪🇬
Assiut University Hospital, Assiut, Egypt

Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up

Phase 4

Withdrawn

Conditions: Migraine Disorders

Interventions: Drug: saline
Drug: bupivacaine

First Posted Date: 2015-10-19

Last Posted Date: 2018-01-23

Lead Sponsor: Bozok University

Registration Number: NCT02578719

Trial of Extended Release Bupivacaine for Pain Relief After Surgery

Phase 3

Completed

Conditions: Post Operative Pain

Interventions: Drug: SABER-Bupivacaine (Part 1)
Drug: SABER-Bupivacaine (Part 2)
Drug: Saline Placebo
Drug: Bupivacaine HCl

First Posted Date: 2015-10-14

Last Posted Date: 2021-07-13

Lead Sponsor: Durect

Target Recruit Count: 399

Registration Number: NCT02574520

Locations: 🇺🇸
Durect Study Site 04, Florence, Alabama, United States
🇺🇸
Durect Study Site 03, Sheffield, Alabama, United States
🇺🇸
Durect Study Site 15, Fontana, California, United States

and more 18 locations

PIEB vs CEI for Labor Analgesia: An MLAC Study

Phase 4

Terminated

Conditions: Pregnancy

Interventions: Drug: Bupivacaine
Drug: Sufentanil

First Posted Date: 2015-10-12

Last Posted Date: 2022-10-18

Lead Sponsor: Stanford University

Target Recruit Count: 31

Registration Number: NCT02573597

Locations: 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy